We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Armata Pharmaceuticals (ARMP) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Armata Pharmaceuticals, Inc. (ARMP - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Armata Pharmaceuticals, Inc. is a member of the Medical sector. This group includes 978 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Armata Pharmaceuticals, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ARMP's full-year earnings has moved 24.7% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ARMP has returned about 36.8% since the start of the calendar year. In comparison, Medical companies have returned an average of -4.5%. As we can see, Armata Pharmaceuticals, Inc. is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Avadel (AVDL - Free Report) . The stock has returned 28.5% year-to-date.
The consensus estimate for Avadel's current year EPS has increased 89.7% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Armata Pharmaceuticals, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 488 individual stocks and currently sits at #97 in the Zacks Industry Rank. On average, stocks in this group have gained 3% this year, meaning that ARMP is performing better in terms of year-to-date returns.
On the other hand, Avadel belongs to the Medical - Drugs industry. This 153-stock industry is currently ranked #80. The industry has moved +8.3% year to date.
Armata Pharmaceuticals, Inc. and Avadel could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Armata Pharmaceuticals (ARMP) Outperforming Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Armata Pharmaceuticals, Inc. (ARMP - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Armata Pharmaceuticals, Inc. is a member of the Medical sector. This group includes 978 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Armata Pharmaceuticals, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ARMP's full-year earnings has moved 24.7% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ARMP has returned about 36.8% since the start of the calendar year. In comparison, Medical companies have returned an average of -4.5%. As we can see, Armata Pharmaceuticals, Inc. is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Avadel (AVDL - Free Report) . The stock has returned 28.5% year-to-date.
The consensus estimate for Avadel's current year EPS has increased 89.7% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Armata Pharmaceuticals, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 488 individual stocks and currently sits at #97 in the Zacks Industry Rank. On average, stocks in this group have gained 3% this year, meaning that ARMP is performing better in terms of year-to-date returns.
On the other hand, Avadel belongs to the Medical - Drugs industry. This 153-stock industry is currently ranked #80. The industry has moved +8.3% year to date.
Armata Pharmaceuticals, Inc. and Avadel could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.